Literature DB >> 8970518

Assessment of fatty acid uptake in ischemic heart disease without myocardial infarction.

M Tateno1, N Tamaki, M Yukihiro, T Kudoh, N Hattori, E Tadamura, R Nohara, T Suzuki, K Endo, J Konishi.   

Abstract

UNLABELLED: To assess the clinical value of 123I fatty acid analog, 123I-beta-methyl iodophenyl pentadecanoic acid (BMIPP) was imaged at rest in coronary patients without prior myocardial infarction. The BMIPP findings were compared with various clinical parameters.
METHODS: Thirty-one patients with ischemic heart disease (19 with unstable angina, 12 with stable angina), without myocardial infarction underwent BMIPP SPECT at rest, coronary arteriography, rest/stress thallium SPECT and left ventriculography exams.
RESULTS: Regional decrease of BMIPP was seen in 63% of the myocardial areas at risk, whereas regional perfusion decrease at rest was observed only in 35% (p < 0.01). The BMIPP decrease was more often seen in the unstable group (79%) than stable group (38%) (p < 0.01). Stress-induced ischemia was seen in 77% of segments with decreased BMIPP uptake in unstable group and in 57% in the stable group. Frequency and severity of BMIPP abnormality increased with the severity of stress-induced ischemia (p < 0.005) and the severity of coronary artery stenosis (p < 0.005). In addition, regional BMIPP abnormality was related to severity of wall motion abnormalities (p < 0.005). While 67% of segments with a wall motion abnormality showed BMIPP decrease, 36% with normal wall motion also showed BMIPP decrease (p < 0.01).
CONCLUSION: Abnormal fatty acid metabolism was often observed at rest in patients with ischemic heart disease without history of myocardial infarction, and the abnormalities were related to severe myocardial ischemia and regional wall motion abnormalities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970518

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

Review 1.  Future aspects of BMIPP.

Authors:  N Tamaki; K Morita; E Tsukamoto; Y Kawai
Journal:  Int J Card Imaging       Date:  1999-02

Review 2.  BMIPP in angina pectoris.

Authors:  S Nishimura; Y Ohta
Journal:  Int J Card Imaging       Date:  1999-02

3.  BMIPP compared with PET metabolism.

Authors:  E Tadamura; N Tamaki; T Kudoh; N Hattori; J Konishi
Journal:  Int J Card Imaging       Date:  1999-02

4.  Perfusion-BMIPP mismatch: specific finding or artifact?

Authors:  Koichi Morita; Eriko Tsukamoto; Nagara Tamaki
Journal:  Int J Cardiovasc Imaging       Date:  2002-08       Impact factor: 2.357

5.  Is BMIPP a sensitive marker for myocardial ischaemic stress? For.

Authors:  Nagara Tamaki; Koichi Morita
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-27       Impact factor: 9.236

6.  Role of BMIPP imaging for risk stratification in patients with coronary artery disease.

Authors:  Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

7.  Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging.

Authors:  Ji Chen; Ernest V Garcia; James R Galt; Russell D Folks; Ignasi Carrio
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

Review 8.  Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations.

Authors:  Keiichiro Yoshinaga; Masanao Naya; Tohru Shiga; Eriko Suzuki; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-12       Impact factor: 9.236

Review 9.  Metabolic imaging using SPECT.

Authors:  Junichi Taki; Ichiro Matsunari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

10.  Quantitative simultaneous 99mTc/123I cardiac SPECT using MC-JOSEM.

Authors:  Jinsong Ouyang; Xuping Zhu; Cathryn M Trott; Georges El Fakhri
Journal:  Med Phys       Date:  2009-02       Impact factor: 4.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.